Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00195286
First received: September 12, 2005
Last updated: September 24, 2009
Last verified: September 2009
  Purpose

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections


Condition Intervention Phase
Urinary Infections
Drug: piperacillin/tazobactam
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Enrollment: 180
Study Start Date: June 2004
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients treated at internal medicine units

Criteria

Inclusion Criteria:

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria:

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00195286

Locations
Spain
Antequera (Málaga), Spain
Avila, Spain
Barcelona, Spain
Berga (Barcelona), Spain
Caceres, Spain
Castellón, Spain
Ciudad Real, Spain
Cuenca, Spain
Cádiz, Spain
Ferrol, Spain
Granada, Spain
Jaen, Spain
Las Palmas, Spain
Lorca (Murcia), Spain
Lugo, Spain
Lérida, Spain
Madrid, Spain
Osuna (Sevilla), Spain
Palma Mallorca, Spain
Pamplona, Spain
Pontevedra, Spain
Terrasa, Spain
Torrelavega, Spain
Valencia, Spain
Valladolid, Spain
Vitoria, Spain
Zaragoza, Spain
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00195286     History of Changes
Other Study ID Numbers: 101315
Study First Received: September 12, 2005
Last Updated: September 24, 2009
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Urinary Infections

Additional relevant MeSH terms:
Infection
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Piperacillin-tazobactam combination product
Penicillanic Acid
Piperacillin
Tazobactam
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 30, 2014